{"id":3915,"date":"2018-12-20T12:22:23","date_gmt":"2018-12-20T08:22:23","guid":{"rendered":"http:\/\/azharmg.com\/?p=3915\/"},"modified":"2018-12-20T12:22:23","modified_gmt":"2018-12-20T08:22:23","slug":"omega-3-meds-not-effective-after-myocardial-infarctions","status":"publish","type":"post","link":"https:\/\/www.azharmg.com\/en\/omega-3-meds-not-effective-after-myocardial-infarctions\/","title":{"rendered":"Omega-3 Meds Not Effective After myocardial infarctions"},"content":{"rendered":"

\"\"<\/p>\n

 <\/p>\n

The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has concluded that omega-3 fatty acid medicines are not effective for secondary prevention after\u00a0<\/span>myocardial infarction<\/a><\/span>\u00a0(MI).<\/span><\/p>\n

Omega-3 fatty acid medicines at a dose of 1\u00a0g per day have been authorized in several European Union countries since 2000 for preventing heart disease or\u00a0<\/span>stroke<\/a><\/span>\u00a0after MI and for lowering high\u00a0<\/span>triglycerides<\/a><\/span>.<\/span><\/p>\n

The Committee’s decision does not affect the authorization of omega-3 fatty acid medicines for the treatment of\u00a0<\/span>hypertriglyceridemia<\/span><\/a>.<\/span><\/p>\n

the large VITAL trial, which found little benefit from omega-3 supplements (or vitamin\u00a0D supplementation) for the prevention of cardiovascular disease.<\/span><\/p>\n

In the\u00a0<\/span>ASCEND trial<\/a><\/span>, a 1\u00a0g dose of omega-3 fatty acids had no effect on serious vascular events (or cancer or mortality) when used for primary prevention in patients with diabetes.<\/span><\/p>\n

However, in the\u00a0<\/span>REDUCE-IT trial<\/a><\/span> 4 g dose of <\/span>\u00a0a high-dose purified form of the omega-3 oil, eicosapentaenoic acid (EPA), in patients with elevated triglycerides who had cardiovascular disease or diabetes and one additional risk factor did show significant benefit, with a 25% relative risk reduction in major adverse cardiovascular events.<\/span><\/p>\n","protected":false},"excerpt":{"rendered":"

  The European Medicine Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) has concluded that omega-3 fatty acid medicines are not effective for secondary prevention after\u00a0myocardial infarction\u00a0(MI). Omega-3 fatty acid medicines at a dose of 1\u00a0g per day have been authorized in several European Union countries since 2000 for preventing heart disease or\u00a0stroke\u00a0after<\/p>\n","protected":false},"author":4,"featured_media":3912,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_joinchat":[],"footnotes":""},"categories":[10],"tags":[],"class_list":["post-3915","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cardiology-cardiac-catheterisation"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/posts\/3915","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/comments?post=3915"}],"version-history":[{"count":1,"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/posts\/3915\/revisions"}],"predecessor-version":[{"id":3916,"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/posts\/3915\/revisions\/3916"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/media\/3912"}],"wp:attachment":[{"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/media?parent=3915"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/categories?post=3915"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.azharmg.com\/en\/wp-json\/wp\/v2\/tags?post=3915"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}